While the Buy rating reaffirms confidence in CRISPR Therapeutics' prospects, the reduction in the price target may reflect a more cautious view of the company's valuation or growth prospects in the short term. This could lead to mixed reactions in the market, with some investors reassured by the continued endorsement and others concerned by the lower valuation estimate.